Objectives To evaluate the risk of venous thromboembolic events associated with the use of
progestin-only contraception and whether that risk differs with the mode of drug delivery (oral…

There is strong evidence linking venous thromboembolic events and malignancy. Laboratory
markers of coagulation activation such as thrombin–antithrombin complex or prothrombin …

Blood microparticles are vesicular structures with a diameter of 100 to 1000 nm that are
present in the blood of normal subjects and in patients with various diseases. These …

Background Low-molecular-weight heparin is the standard treatment for cancer-associated
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …

Purpose: Despite the strong association between malignant disease and thromboembolic
disorders, the molecular and cellular basis of this relationship remains uncertain. We …

Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state with a high
incidence of thrombotic events during hospitalization; however, data examining rates of …

In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite
outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients …

We developed a personalized cancer vaccine in which patient-derived acute myeloid
leukemia (AML) cells are fused with autologous dendritic cells, generating a hybridoma that …

Elevated levels of circulating tissue factor‐bearing microparticles ( TFMP ) have been
associated with an increased risk of developing venous thromboembolism ( VTE ) in cancer …

Lenalidomide is an effective therapeutic agent for multiple myeloma that exhibits
immunomodulatory properties including the activation of T and NK cells. The use of lenalidomide to …